Dossier assessment
Glycopyrronium (axillary hyperhidrosis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Glycopyrronium (axillary hyperhidrosis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Glycopyrronium (axillary hyperhidrosis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adult patients with severe primary axillary hyperhidrosis
Result of dossier assessment:
Added benefit not proven
Project details
- Project no.
- A22-82
- Commission
- Commission awarded on 01.08.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.